Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
- H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner
- The New England journal of medicine
- 20 September 2001
Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug. Expand
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Acarbose could be used, either as an alternative or in addition to changes in lifestyle, to delay development of type 2 diabetes in patients with impaired glucose tolerance. Expand
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
This study suggests that treating IGT patients with acarbose is associated with a significant reduction in the risk of cardiovascular disease and hypertension. Expand
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs. Expand
Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study
The Di@bet.es Study shows, for the first time, the prevalence rates of diabetes and impaired glucose regulation in a representative sample of the Spanish population, and was higher in men than in women. Expand
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
The interim findings from this ongoing study were inconclusive regarding the effect of rosiglitazone on the overall risk of hospitalization or death from cardiovascular causes. Expand
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes. Expand
Mitofusin 2 in POMC Neurons Connects ER Stress with Leptin Resistance and Energy Imbalance
It is shown that mitochondria-ER contacts in anorexigenic pro-opiomelanocortin neurons in the hypothalamus are decreased in diet-induced obesity, establishing MFN2 in POMC neurons as an essential regulator of systemic energy balance by fine-tuning the mitochondrial-ER axis homeostasis and function. Expand
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study
- R. Gomis, R. Espadero, R. Jones, H. Woerle, K. Dugi
- Diabetes, obesity & metabolism
- 1 July 2011
Aims: To compare the efficacy, safety and tolerability of linagliptin or placebo administered for 24 weeks in combination with pioglitazone in patients with type 2 diabetes mellitus (T2DM) exhibiting… Expand
Hypothalamic and brainstem neuronal circuits controlling homeostatic energy balance.
Current knowledge on the homeostatic regulation of energy balance is reviewed, emphasizing recent advances in mouse genetics, electrophysiology, and optogenetic techniques that have greatly contributed to improving understanding of this central process. Expand